trending Market Intelligence /marketintelligence/en/news-insights/trending/1n3feuiuratmxigaj1lgfa2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Ophthotech adds former Santen CEO to board

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates

Blog

COVID-19 Impact & Recovery: Investment Banking


Ophthotech adds former Santen CEO to board

Ophthotech Corp. has elected Adrienne Graves to be a board member, effective Dec. 12.

Graves is the former CEO of Santen Inc., the U.S. arm of Japan-based ophthalmic pharmaceutical company Santen Pharmaceutical Co. Ltd.

In addition, Michael Ross will step down as an independent board member at the end of February 2019.

New York-based Ophthotech is a biopharmaceutical company specializing in the development of novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases.